Skip to main content

We've updated our Privacy Policy. Questions? Email us any time at privacy@ground.news

SubscribeLogin
Published • loading... • Updated

Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera

Summary by WBOC 16
Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering

8 Articles

STATSTAT
Center

Silence Therapeutics aims at Takeda with new data in rare blood cancer

Silence's polycythemia vera drug, called divesiran, could compete with a Takeda drug nearing approval called rusfertide.

·Boston, United States
Read Full Article
WBOC 16WBOC 16
+5 Reposted by 5 other sources
Center

Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera

Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering

Read Full Article
Business WireBusiness Wire

Silence Therapeutics to Host Conference Call and Webcast to Discuss ...

·Crystal River, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 80% of the sources are Center
80% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Business Wire broke the news in Crystal River, United States on Sunday, August 9, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

London, England icon

London, England

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal